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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comAKI comprised among others non-transfemoral access, anemia, high EURO Score and
the absence of an increase in cardiac output (CO) after TAVI (AKI vs. non-AKI DCO:
0.28.6% vs. 7.226.5%, p< 0.0001).
Conclusions: Preprocedural renal dysfunction has a prominent impact on mortality
after TAVI. In addition, the occurrence of AKI after TAVI carries an even worse
prognosis. In this regard, the maintenance of a sufﬁcient blood pressure and
an increase of cardiac output after TAVI seem to be protective against renal
impairment.
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Background: Neutrophil gelatinase-associated lipocalin (NGAL) is a novel
biomarker associated with acute kidney injury (AKI) after cardiac procedures. NGAL
allows earlier detection of AKI than serum creatinine (SCr) level but has not been
evaluated post transcatheter aortic valve replacement (TAVR).
Methods: From 6/2012-5/2013, we enrolled 66 patients undergoing TAVR in this
single-center pilot study. Urinary NGAL was measured at baseline, 2, 4, and 12 hours
post op. Demographic, procedural features, and SCr until discharge were measured.
The trend of NGAL post TAVR and the association of increased NGAL with AKI as
per VARC-2 criteria was assessed.
Results: Twenty-two patients (33.3%) developed AKI postoperatively (Stage 1,
63.6%; Stage 2, 22.7%; Stage 3, 13.6%). There was no signiﬁcant difference in
baseline SCr, eGFR, or contrast dye volume between patients who developed AKI and
those who did not but AKI patients had a signiﬁcantly smaller aortic valve area. There
was a signiﬁcantly higher level of NGAL in patients with AKI versus those without
AKI seen at 2, 4 and 12 hours post procedure (Figure), with the peak at 2 hours. After
adjusting for gender, age, diabetes, TAVR type, and BMI; NGAL was signiﬁcantly
predictive of AKI at baseline (OR ¼ 1.019 (95% CI 1.001 – 1.037, p¼0.034) and at
each post op measurement.
Conclusions: NGAL was signiﬁcantly elevated in patients who develop AKI both pre
TAVR and post TAVR as early as 2 hours post procedure in this pilot study. This
biomarker may assist in better determining patients at risk for and earlier detection and
management of this frequent complication.TCT-760
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Background: An association between the acquired von Willebrand syndrome
(aVWS) and valvular aortic stenosis (AVS) has been demonstrated in the past.
While the extend of von Willebrand factor (aVWF) deﬁciency is related to the
severity of AVS, surgical valve replacement (SAVR) can lead to factor recovery.
Prevalence and course of the aVWS in patients treated with TAVR though has not
yet been described comprehensively. Thus, we investigated the prevalence of the
aVWS in patients undergoing TAVR and the impact on the underlying factor
variances.
Methods: 104 consecutive patients (age: 81.0  13.0years; logEUROscore
22.918.5%) underwent TAVR at our institution. Comprehensive hemostaseologic
testing was performed prior to and up to one week after TAVR. Transvalvular he-
modynamics and right heart catheterisation as well as bleeding episodes were recorded
and analyzed with descriptive statistics.
Results: Baseline prevalence of an aVWS was 41% with an average densitometric
high-molecular-weight multimer (HMW-MM) count of 16.63.5%. Pressure gradi-
ents correlated signiﬁcantly with the extent of high-molecular-weight multimere
(HMW-MM) deﬁciency (r¼-0.63 [P< 0.0001]). While in the past it has been shown to
be vice-versa for SAVR, the necessity of blood transfusions was higher in our control-
group1. Following valve implantation, HMW-MM increased proportional to the drop
in mean pressure gradient and normalized within a week in 97% of the patients with
prior aVWS.
Conclusions: We describe a signiﬁcant prevalence of aVWS in patients undergoing
TAVR. Since severe factor deﬁciency can lead to signiﬁcant bleeding during SAVR,
TAVR should be taken into consideration as a ﬁrst line treatment for patients with
AVS and concomitant aVWS.
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Background: Balloon aortic valvuloplasty (BAV) has traditionally been part of the
transcatheter aortic valve implantation (TAVI) procedure using balloon expandable
valves. However, the beneﬁt of this is unknown. We aimed to evaluate procedural
success and safety in patients who underwent TAVI with and without BAV.
Methods: We retrospectively evaluated all TAVIs performed for predominant aortic
stenosis using the balloon-expandable Edwards Sapien XT and Sapien 3 devices
from March 2012 to April 2014. BAV was routinely performed only until May 2013.
We assessed Valve Academic Research Consortium (VARC)-2 deﬁned device suc-
cess and safety; differences in procedure and ﬂuoroscopy times and differences in
embolic load based on transcranial Doppler (TCD). Categorical variables were
analyzed using the Fisher exact test and continuous variables by the unpaired T-test
on SPSS v21.
Results: 61 patients underwent BAV (Group 1) and 52 patients had no BAV (Group
2). There was no difference (p>0.05) in the rate of device success, speciﬁcally
successful valve deployment (98.3% in Group 1 and 96.1% in Group 2), rate of
post-deployment balloon dilatation (3.4% in Group 1 and 4.0% in Group 2) or
incidence of moderate or severe aortic regurgitation (4.9% in Group 1 and 5.8% in
Group 2). There were no differences in procedure safety (50.8% VARC-2 deﬁned
major and minor complications in Group 1 and 34.6% in Group 2, p¼0.15). In one
case there was difﬁculty in crossing the valve without BAV, partial inﬂation of the
distal balloon tip within the TAVI valve enabled crossing of the native aortic valve
without subsequent deployment problems. There was a reduction in total ﬂuoro-
scopic time in Group 2 vs Group 1 (13.2 vs 17.3 mins, p¼0.006), but no signiﬁcant
difference in total procedure time (112 vs 119 mins, p¼0.21).There were no dif-
ferences between the 2 groups in terms of number of solid, gaseous or total emboli
on TCD (all p>0.05).
Conclusions: Balloon-expandable TAVI valves can be implanted transfemorally
without BAV, without a reduction in VARC-2 deﬁned success or safety. Without
performing a BAV there is a signiﬁcant reduction in the ﬂuoroscopic time. There is no
difference in the rate of embolization on TCD.
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Background: Transcatheter aortic valve implantation (TAVI) is the new standard of
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